Lentino J R, Stachowski M, Strikas R, Parrillo P
Antimicrob Agents Chemother. 1984 Jun;25(6):778-80. doi: 10.1128/AAC.25.6.778.
Cefotiam was evaluated by a comparative open-label randomized trial with cephalothin in the therapy of skin and soft tissue infections in 39 patients. The most common organism isolated was Staphylococcus aureus (78%). We established evidence of primary infection with gram-negative bacilli in four patients, three of whom were diabetic. Eight patients had mixed infections or superinfections. No patient was evaluated as a treatment failure; for 10 of 39 patients we were unable to recover an etiological agent but demonstrated a clinical cure. Cefotiam was found to be as effective as cephalothin in the therapy of skin and soft tissue infections.
通过一项开放性随机对照试验,比较了头孢替安和头孢噻吩对39例皮肤及软组织感染患者的疗效。分离出的最常见病原体为金黄色葡萄球菌(78%)。我们确定有4例患者为革兰氏阴性杆菌原发性感染,其中3例为糖尿病患者。8例患者有混合感染或二重感染。没有患者被评估为治疗失败;39例患者中有10例未能分离出病原体,但显示临床治愈。结果发现头孢替安在治疗皮肤及软组织感染方面与头孢噻吩同样有效。